Nurix Therapeutics (NRIX) said Wednesday it received PRIME designation from the European Medicines Agency for NX-5948 to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The PRIME, or priority medicines, designation follows "encouraging" safety and efficacy data from an ongoing phase 1 trial, the company said.
To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data, the firm said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.